Sanofi Adds 4 Long-Acting Antibodies for USD 1Bn

Long-acting immunology antibodies are becoming an important part of Sanofi and Regeneron's strategy to extend their work in type 2 inflammation beyond Dupixent.

The companies have expanded their more than 20-year collaboration by adding four next-generation antibodies, with Sanofi paying Regeneron USD 1 billion upfront and potentially another USD 7 billion in milestones.

The agreement includes REGN20423, a Phase 1 IL-13 antibody, alongside an IL-4xIL-13 bispecific and two other long-acting preclinical antibodies.

With more than 1.5 million people receiving Dupixent across nine indications, the expansion provides a closer look at how the partners are developing the next generation of immunology therapies.

How is Sanofi building beyond Dupixent with new antibodies?

The agreement's pharmaceutical significance lies in the four antibody approaches, not just its financial value. The expanded collaboration covers long-acting antibodies against IL-13, IL-4 and IL-4Rα, as well as an IL-4xIL-13 bispecific antibody.

REGN20423 is already being evaluated in a Phase 1 study for atopic dermatitis, while the other three candidates are expected to enter clinical studies in 2027.

This expands the firm’s focus across pathways central to type 2 inflammation. Dupixent, or dupilumab, blocks IL-4 and IL-13 signaling through IL-4Rα.

The new portfolio therefore explores different ways of modulating the same biological network, including direct cytokine targeting and dual-pathway inhibition.

Also Read: World Heart Day 2026: 8 Ways to Protect Your Heart Every Day

Why are IL-4 and IL-13 important in immunology drug development?

IL-4 and IL-13 are key drivers of type 2 inflammation and have relevance across several allergic and inflammatory diseases.

Dupixent's development helped establish the clinical importance of inhibiting these pathways, while the new candidates let Regeneron test whether different antibody designs can offer additional therapeutic options.

The IL-4xIL-13 bispecific antibody is particularly notable because it is designed to address both cytokine pathways in a single molecule. Meanwhile, the long-acting IL-13 and IL-4 antibodies represent further exploration of targeted pathway inhibition.

These candidates remain investigational, so their clinical differentiation from established treatments will depend on future efficacy and safety data.

Could long-acting antibodies change treatment approaches?

The long-acting design also brings a pharmaceutical-development question beyond target selection: how frequently can effective pathway suppression be maintained? 

Longer-acting antibodies may potentially support less frequent administration and sustained target engagement, although these benefits need to be demonstrated clinically for each candidate.

Regeneron's pipeline presentation has identified longer Dupixent dosing intervals and next-generation IL-4Rα, IL-13, IL-4 and IL-4xIL-13 approaches as part of its strategy in type 2 diseases.

The expanded portfolio therefore combines target biology with antibody engineering, giving the partnership multiple approaches to investigate within the same immunology space.

What will the four antibodies need to demonstrate clinically?

The development stages highlight the uncertainty still surrounding the portfolio. REGN20423 is in Phase 1, while three candidates have yet to enter clinical studies.

The key question will be whether their long-acting profiles or differentiated target mechanisms translate into meaningful clinical benefits over existing therapies.

That makes the agreement more than a pipeline expansion: it creates a series of clinical experiments around established type 2 inflammation biology. The outcome will depend on evidence generated across safety, efficacy, dosing and durability.

Why are Sanofi and Regeneron expanding the alliance now?

On the business side, Sanofi will pay USD 1 billion upfront, with up to another USD 7 billion in development, regulatory and commercial milestones.

The companies will share development and commercialization costs and future profits 50:50, while Regeneron leads R&D and Sanofi leads global commercialization. The agreement also settles their previous collaboration-related litigation.

The existing Dupixent profit-sharing arrangement remains unchanged, keeping the new portfolio structurally separate from the established product economics.

This expansion consequently positions the Sanofi-Regeneron partnership around next-generation immunology development, with long-acting antibodies and multi-target approaches forming the core of its effort to build beyond Dupixent.